Richard Lathe mailto:rlathe@ed.ac.uk?Subject=From letter in Psychiatry On-Line&CC=ben@priory.com
Sir - I write to report adverse
effects of venlafaxine from observations on one subject and from a wider survey
of the literature. One subject receiving venlafaxine (Efexor XL, 75 mg/day) for
6 months reported headaches and related symptoms of severity sufficient to
preclude normal function. Discontinuation was found impossible, medication was
recommenced according to a schedule for tapered removal.
Following
complete discontinuation the headaches disappeared, but investigation revealed
that the subject had experienced debilitating inertia for the period of the
medication. Longer-term problems have also became apparent: 1 month later the
subject still reports sudden episodes of nausea, temporary disconnection,
palpitations, tremor, sweating, unsteadiness.
On investigation I find
that this is not unusual. There is a volume of literature on the acute and
chronic adverse effects of discontinuing Venlafaxine, including nausea, memory
loss, tinnitis, altered sleep patterns, digestive disturbances, and tremor,
termed the 'serotonin syndrome' (1). Indeed, the manufacturer (Wyeth) could face
charges for failure to issue proper warnings (2). New guidance from the FDA
recognises the adverse consequences of Venlafaxine discontinuation (4). It is
notable that the information issued with Venlafaxine (Efexor XL) in November
2001 only speaks of transient adverse effects 'for a few days' (5).
In
summary, the prominent side-effects (6) including debilitating inertia are
clearly undesirable when comparable results can be obtained with other
therapies(7). Further, the duration of medication here (8 months) is, as far as
I can establish, longer than the maximum period of clinical trials 8): a strong
argument can be made that the drug administration should be restricted to less
than 6 months, with tapered discontinuation scheduled from inception.
Richard Lathe
Biomedical
Sciences, Faculty of Medicine, University of Edinburgh, George
Square,
Edinburgh EH8 9LS, UK (rlathe@ed.ac.uk)
References
1.http://www.effexorfx.freeuk.com/index.htm.
2.Guardian, Thursday September 6, 2001;
Drug giant faces huge
lawsuit.
http://society.guardian.co.uk/mentalhealth/story/0,8150,547606,00.html
4.Food
and Drug Administration, March 2000. Safety Related Drug Labelling Changes for
Effexor and Effexor XR.
5.Information sheet, Efexor XL, November 2001 (Wyeth
Laboratories, Taplow, Maidenhead, UK). "If Efexor XL is stopped suddenly some
patients may experience symptoms ..... these symptoms are generally non-serious
and disappear within a
few
day".
6.http://www.athealth.com/Consumer/mcabinet/EffexorXR.html#AdverseEvents
7.
http://www.effexor.com/hcp/remission/data.jhtml.
8.
http://www.effexor.com/hcp/overview/efficacy-depression.jhtml
All pages copyright ©Priory Lodge Education Ltd 1994-2003.